BioCryst Pharmaceuticals Inc
BCRX8.325USD
+0.375+4.72%
Market hours （ET）Quotes delayed by 15 min
1.74BMarket Cap
LossP/E TTM
More Details of BioCryst Pharmaceuticals Inc Company
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.
Company Info
Ticker SymbolBCRX
Company nameBioCryst Pharmaceuticals Inc
IPO dateMar 04, 1994
CEOMr. Charles K. Gayer
Number of employees580
Security typeOrdinary Share
Fiscal year-endMar 04
Address4505 Emperor Blvd Ste 200
CityDURHAM
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code27703-8457
Phone19198591302
Websitehttps://www.biocryst.com/
Ticker SymbolBCRX
IPO dateMar 04, 1994
CEOMr. Charles K. Gayer
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Mr. Vincent J. Milano
Mr. Vincent J. Milano
Independent Director
Independent Director
89.76K
+16.18%
Dr. Steven K. Galson, M.D.
Dr. Steven K. Galson, M.D.
Independent Director
Independent Director
70.87K
+21.41%
Mr. Alan G. Levin
Mr. Alan G. Levin
Independent Director
Independent Director
64.27K
+24.14%
Dr. Amy E. Mckee, M.D.
Dr. Amy E. Mckee, M.D.
Independent Director
Independent Director
40.33K
+44.91%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jon P. Stonehouse
Mr. Jon P. Stonehouse
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
939.88K
-20.60%
Mr. Charles K. Gayer
Mr. Charles K. Gayer
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
237.81K
-26.43%
Ms. Alane P. Barnes
Ms. Alane P. Barnes
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
215.03K
-26.71%
Dr. Helen M. Thackray, M.D.
Dr. Helen M. Thackray, M.D.
Chief Research & Development Officer
Chief Research & Development Officer
161.62K
-26.06%
Mr. Babar Ghias
Mr. Babar Ghias
Chief Financial Officer, Head of Corporate Development
Chief Financial Officer, Head of Corporate Development
147.00K
--
Dr. Nancy J. Hutson, Ph.D.
Dr. Nancy J. Hutson, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
99.14K
+14.43%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Jul 12
Updated: Sat, Jul 12
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
10.33%
BlackRock Institutional Trust Company, N.A.
8.55%
Kynam Capital Management LP
4.27%
Avoro Capital Advisors LLC
4.16%
State Street Global Advisors (US)
3.73%
Other
68.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
32.45%
Investment Advisor/Hedge Fund
29.96%
Hedge Fund
18.97%
Research Firm
3.20%
Private Equity
1.84%
Individual Investor
1.27%
Pension Fund
0.53%
Bank and Trust
0.41%
Sovereign Wealth Fund
0.25%
Other
11.14%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
549
185.97M
88.87%
-12.50M
2025Q1
560
182.40M
87.18%
-20.97M
2024Q4
556
172.66M
82.64%
-37.08M
2024Q3
554
179.19M
86.60%
-34.24M
2024Q2
532
180.82M
87.59%
-35.90M
2024Q1
546
187.78M
91.10%
-27.21M
2023Q4
549
183.67M
89.35%
-28.91M
2023Q3
542
183.90M
96.89%
-26.67M
2023Q2
545
181.25M
95.65%
-20.15M
2023Q1
554
177.87M
94.17%
-5.12M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
21.61M
10.33%
-230.66K
-1.06%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
17.89M
8.55%
+189.84K
+1.07%
Mar 31, 2025
Kynam Capital Management LP
8.93M
4.27%
-156.84K
-1.73%
Mar 31, 2025
Avoro Capital Advisors LLC
8.70M
4.16%
-3.17M
-26.68%
Mar 31, 2025
State Street Global Advisors (US)
7.81M
3.73%
+314.44K
+4.19%
Mar 31, 2025
Alkeon Capital Management LLC
6.00M
2.87%
+109.73K
+1.86%
Mar 31, 2025
Two Sigma Investments, LP
5.27M
2.52%
+992.22K
+23.22%
Mar 31, 2025
Deerfield Management Company, L.P.
5.19M
2.48%
-2.95M
-36.28%
Mar 31, 2025
Geode Capital Management, L.L.C.
4.96M
2.37%
+136.90K
+2.84%
Mar 31, 2025
RP Management, LLC
3.85M
1.84%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Genomics Immunology and Healthcare ETF
3.3%
Invesco Biotechnology & Genome ETF
2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
1.83%
Virtus LifeSci Biotech Products ETF
1.66%
ALPS Medical Breakthroughs ETF
1.27%
SPDR S&P Biotech ETF
0.68%
First Trust Small Cap Growth AlphaDEX Fund
0.66%
Main Thematic Innovation ETF
0.58%
Direxion Daily S&P Biotech Bull 3X Shares
0.39%
Invesco NASDAQ Future Gen 200 ETF
0.38%
View more
iShares Genomics Immunology and Healthcare ETF
Proportion3.3%
Invesco Biotechnology & Genome ETF
Proportion2.21%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.83%
Virtus LifeSci Biotech Products ETF
Proportion1.66%
ALPS Medical Breakthroughs ETF
Proportion1.27%
SPDR S&P Biotech ETF
Proportion0.68%
First Trust Small Cap Growth AlphaDEX Fund
Proportion0.66%
Main Thematic Innovation ETF
Proportion0.58%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.39%
Invesco NASDAQ Future Gen 200 ETF
Proportion0.38%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
